INDP
Indaptus Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.22
+5.17%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | — | — | — |
| Cost of Revenue | — | — | — | — | — |
| Gross Profit | — | — | — | — | — |
| Operating Expenses | |||||
| R&D Expense | 5.2M | 9.3M | 7.3M | 7.6M | 6.3M |
| SG&A Expense | 9.6M | 10.5M | 8.1M | 8.8M | 8.6M |
| General & Admin Expense | 9.6M | 10.5M | 8.1M | 8.8M | 8.6M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | — | — | 0.00 | — | — |
| Total Operating Expenses | 14.8M | 19.8M | 15.4M | 16.4M | 14.9M |
| Cost and Expenses | 14.8M | 19.8M | 15.4M | 16.4M | 14.9M |
| Operating Income (EBIT) | (14.8M) | (19.8M) | (15.4M) | (16.4M) | (14.9M) |
| Non-Operating | |||||
| Interest Income | — | — | — | — | 588.1K |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | 588.1K |
| Other Non-Op Income/Expense | (650.9K) | (1.0M) | 343.7K | 955.0K | 588.1K |
| Non-Operating Income (excl Interest) | 678.9K | 1.0M | (343.7K) | (955.0K) | (588.1K) |
| EBT (Pre-Tax Income) | (15.4M) | (20.8M) | (15.0M) | (15.4M) | (14.3M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (15.4M) | (20.8M) | (15.0M) | (15.4M) | (14.3M) |
| Earnings from Cont. Ops | (15.4M) | (20.8M) | (15.0M) | (15.4M) | (14.3M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (15.4M) | (20.8M) | (15.0M) | (15.4M) | (14.3M) |
| Per Share | |||||
| Basic EPS | ($6.97) | ($21.58) | ($44.96) | ($51.41) | ($48.54) |
| Diluted EPS | ($6.97) | ($21.58) | ($44.96) | ($51.41) | ($48.54) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 116.1M | 966124 | 334132 | 300037 | 295075 |
| Diluted Shares Outstanding | 116.1M | 966124 | 334132 | 300037 | 295075 |
| Profitability Metrics | |||||
| EBITDA | (15.5M) | (20.8M) | (15.0M) | (15.4M) | (14.3M) |
| D&A | — | — | 735.00 | 1.3K | 1.8K |
| EBIT | (15.5M) | (20.8M) | (15.0M) | (15.4M) | (14.3M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026